#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Neurodevelopmental disorder B-cell small lymphocytic lymphoma IgA nephropathy Adenovirus infection Glycogen storage disease type II Granulomatosis with polyangiitis Anti-neutrophil cytoplasmic antibody positive vasculitis Mitochondrial myopathy Chronic graft versus host disease Peripheral T-cell lymphoma unspecified Retinopathy of prematurity Hepatic angiosarcoma Extraskeletal ossification Sickle cell disease Hodgkin's disease More trials…

    Learn about Rare Diseases

    Pleomorphic leiomyosarcoma – Life with Disease Cholangitis sclerosing – Basic Information Mast cell activation syndrome – Life with Disease Lysosomal storage disorder – Life with Disease Choroid melanoma – Diagnostics Mast cell activation syndrome Hepatic angiosarcoma – Treatment Biotinidase deficiency – Basic Information Glycogen storage disease type II Mucopolysaccharidosis – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Selexipag Anhydrous Benzoyl Peroxide L-Ascorbic Acid Ranitidine Hydrochloride Ecubectedin Cytisine Ddcart‐Cd19 Ripretinib Pp1815 IDOR-1117-2520C Magnesium Citrate Sodium Zirconium Cyclosilicate Csm-Gw Buserelin Acetate Ixazomib TALADEGIB JNJ-75276617 Ropivacaine Hydrochloride Ly3871801 Enalapril More therapies…

    Learn about Your Condition

    Circulatory collapse Hepatic cirrhosis Andersen-Tawil syndrome Tympanic membrane perforation Breast cancer stage II Adenovirus infection Myopia Spermatocele HIV infection Leukoencephalopathy Neurodermatitis Ichthyosis Neonatal anoxia Organ donor Leiomyosarcoma recurrent More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. NZOZ Neuro- Kard Ilkowski i Partnerzy Spółka Partnerska…

NZOZ Neuro- Kard Ilkowski i Partnerzy Spółka Partnerska Lekarzy

Ul. Wierzbowa 2/2, Poznan, 61-853, Poland

Want to learn more about this study or check if you can participate? Contact us.

  • A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis

    Recruiting

    3 1
    Austria Belgium Bulgaria Croatia Czechia Denmark +15

  • Phase 2 Randomized Study of Povetacicept to Assess Safety and Effectiveness in Adults with Generalized Myasthenia Gravis

    Recruiting

    2 1
    Investigated Diseases:
    • Myasthenia gravis
    Investigated Drugs:
    • Povetacicept
    Poland

  • Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis

    Recruiting

    3 1
    Austria Belgium Bulgaria Croatia Czechia Denmark +14

  • A study to evaluate the safety and how the body uses ublituximab injections in patients with multiple sclerosis

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Ublituximab
    Poland

  • A study of IM-101 in adults with generalized myasthenia gravis or ocular myasthenia gravis

    Recruiting

    1 1 1
    Investigated Drugs:
    • HAEMOPHILUS TYPE B POLYSACCHARIDE CONJUGATED TO TETANUS TOXOID ADSORBED ON ALUMINIUM PHOSPHATE
    • HEPATITIS B SURFACE ANTIGEN (RDNA) ADSORBED ON ALUMINIUM PHOSPHATE [PRODUCED IN S. CEREVISAE CELLS BY RDNA]
    • MENINGOCOCCAL GROUP Y OLIGOSACCHARIDE CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE CRM197 PROTEIN
    Bulgaria Italy Poland Spain

  • A study of RO7268489 added to ocrelizumab compared to placebo in adults with progressive multiple sclerosis

    Recruiting

    2 1 1
    Investigated Diseases:
    • Multiple sclerosis
    Investigated Drugs:
    • RO7268489
    • Ocrelizumab
    France Germany Hungary Italy Poland Portugal +1

  • Study on the Safety and Effectiveness of IPN10200 for Treating Upper Limb Spasticity in Adults After Stroke or Brain Injury

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Botulinum Toxin Type A – Haemagglutinin Complex
    • Clostridium Botulinum, Neurotoxin Serotype A/B
    Austria Bulgaria Czechia France Germany Hungary +4

  • Study on the Effectiveness of Ublituximab and Drug Combination for Patients with Relapsing Multiple Sclerosis

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Relapsing multiple sclerosis
    Investigated Drugs:
    • Cetirizine
    • Gadobutrol
    • Ublituximab
    Poland

  • Study on BI 690517 and Empagliflozin for Patients with Heart Failure and Preserved Ejection Fraction

    Recruiting

    3 1 1
    Investigated Diseases:
    • Cardiac failure
    Investigated Drugs:
    • Bi 690517
    • Empagliflozin
    Belgium Bulgaria Czechia Germany Hungary Italy +5

  • Study on the Effects of Vidofludimus Calcium (IMU-838) in Patients with Progressive Multiple Sclerosis

    Recruiting

    2 1
    Investigated Diseases:
    • Progressive multiple sclerosis
    Investigated Drugs:
    • Vidofludimus Calcium
    Bulgaria Czechia Germany The Netherlands Poland Romania
1 2 3 4
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!